地西他滨治疗MDS及AML临床研究进展.pdfVIP

目录

小剂量地西他滨或阿扎胞苷治疗MDSIPSS低危、中危-1患者的随机II期临床研究初步结

果3

极低剂量地西他滨和剂量去甲基化药物治疗MDS的比较5

地西他滨表观遗传学预处理序贯阿糖胞苷作为诱导方案治疗新诊断的急性髓细胞性白血病

老年患者7

接受去甲基化药物治疗的MDS患者的长期结局：MDS临床研究9

去甲基化药物治疗慢性粒-单核细胞白血病的长期疗效：单经验11

去甲基化药物治疗获得疾病稳定的MDS患者的预后13

7号异常的MDS患者的临床特征和治疗模式：国际多研究提示去甲基化药物显

著改善IPSS-R极高危MDS患者的总和无AML15

获得完全缓解或部分缓解后停止HMA治疗：对长期随访的回顾性分析17

目录

PreliminaryresultsofrandomizedphaseIIclinicalstudyinlow-risk,-risk-1

patientswithlow-dosedecitabineorazacitidinetreatmentofMDSIPSS.3

ComparisonofextremelylowdosedecitabineandstandarddosedemethylationdrugsforMDS.5

Decitabineepigeneticpretreatmentofsequentialcytarabineasaninductionregimen

forthetreatmentofnewlydiagnosedacutemyeloidleukemiainelderlypatients.7

Long-termoutcomesofMDSpatientstreatedwithdemethylation:MDSClinicalResearchAlliancereports9

Long-termefficacyofdemethylationdrugsinthetreatmentofchronicmyeloid-monocyticleukemia:single-center

experience11

Demethylationdrugtreatmenttoobtainprognosisinpatientswithdisease-stableMDS.13

Clinicalcharacteristicsandtreatmentpatternsofpatientswithchromosome7abnormalities:

Internationalmulticenterstudysuggeststhatdemethylateddrugssignificantlyimproveoverall

survivalandAML-freesurvivalinpatientswithextremelyhigh-riskMDSatIPSS-R15

DiscontinuationofHMAtreatmentafterobtainingcompleteorpartialremission:aretrospectiveanalysisoflong-term

follow-upsurvival17

小剂量地西他滨或阿扎胞苷治疗MDSIPSS低危、中危-1患者的随机II期临床